Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

Inhibitors of poly(ADP‐ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In our study, of 182 women with EOC treated with PARPi, 16 (8.7%...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Todisco, Elisabetta, Gigli, Federica, Ronchini, Chiara, Amato, Viviana, Sammassimo, Simona, Pastano, Rocco, Parma, Gabriella, Lapresa, Maria Teresa, Bertolini, Francesco, Corsini, Chiara, Gregato, Giuliana, Poletti, Claudia, Pelicci, Pier Giuseppe, Alcalay, Myriam, Colombo, Nicoletta, Tarella, Corrado
Format: Online Artykuł Texto
Język:English
Wydane: John Wiley & Sons, Inc. 2022
Hasła przedmiotowe:
Cancer Therapy and Prevention
Dostęp online:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Podobne zapisy